Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice
- 7 February 2022
- journal article
- research article
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 29 (4) , 359-368
Abstract
Introduction: Diabetes mellitus (DM) is a risk factor for Alzheimer’s disease (AD). Increasing evidence indicates that the triggering receptor expressed on myeloid cells (TREM)-1 amplifies chronic inflammation, as well as the roles of prolactin (PRL) and metformin (MET) in tau hyperphosphorylation. However, the associations among TREM-1, tau hyperphosphorylation, PRL expression, and MET in DM remain unclear. Methods: Streptozotocin was used to induce experimental DM in C57BL/6N mice. MET was orally administered at a dose of 400 mg/kg body weight for 6 weeks prior to hippocampal collection in DM mice. Various parameters pertaining to the TREM-1 pathway, tau hyperphosphorylation, PRL, and related factors were analyzed. Results: Quantitative polymerase chain reaction and Western blot analysis demonstrated that the expression levels of TREM-1, DAP12, casp1, interleukin-1β, Cox2, inducible nitric oxide synthase, pituitary transcriptional factor-1 (Pit-1), and PRL were significantly increased in the hippocampus of DM mice; the expression levels of these pro-inflammatory mediators, PRL receptor (PRLR) short or long (PRLR-S and PRLR-L), and PRL regulatory element-binding (Preb) protein in DM mice treated with MET (DM + MET) were significantly decreased compared with those in control (CON) mice. The levels of p-Tau and glycogen synthase kinase-3 in the DM group were significantly higher than those in the CON group and significantly lower than those in the DM + MET group. Conclusion: We confirmed the therapeutic potential of MET for both DM and neurodegeneration. Our findings shed new light on the effects of DM on the pathophysiology of AD via the TREM-1 pathway and PRL expression. Thus, an improved understanding of the TREM-1 pathway in hyperglycemic conditions, as well as PRL, Preb, Pit-1, PRLR-L, and PRLR-S gene expression in the liver, brain, and other sites, may help unravel the pathogenesis of insulin resistance and neurodegeneration.Keywords
This publication has 18 references indexed in Scilit:
- Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?BMC Endocrine Disorders, 2013
- Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant micePharmacology Biochemistry and Behavior, 2012
- Central Nervous System Fibrosis Is Associated with Fibrocyte-Like InfiltratesThe American Journal of Pathology, 2011
- Increased Tau Phosphorylation and Cleavage in Mouse Models of Type 1 and Type 2 DiabetesEndocrinology, 2009
- The TREM-1/DAP12 pathwayImmunology Letters, 2008
- Alzheimer-Like Changes in Rat Models of Spontaneous DiabetesDiabetes, 2007
- Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer miceExperimental Neurology, 2006
- Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive FunctionArchives of Neurology, 2004
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004
- A Dap12-Mediated Pathway Regulates Expression of Cc Chemokine Receptor 7 and Maturation of Human Dendritic CellsJournal of Experimental Medicine, 2001